A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

Clinical trial NCT07222137 · RECRUITING

Trial details

NCT number: NCT07222137
Sponsor: Eli Lilly and Company
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Diabetes Mellitus, Type 1

Start date: 2026-01-12
Primary completion: 2031-07-01
Enrollment: 150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.